Triple-negative breast cancer: Role of the androgen receptor

Cancer Journal

Volumn 16, Issue 1, 2010, Pages 62-65

  Gucalp, Ayca ^a   Traina, Tiffany A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Androgen receptor; Hormone receptor; Triple negative breast cancer

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GONADORELIN AGONIST; PROGESTERONE RECEPTOR;

ABDOMINAL PAIN; ADVANCED CANCER; ANEMIA; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER HORMONE THERAPY; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE TARGETING; GYNECOMASTIA; HIRSUTISM; HORMONE RECEPTOR INTERACTION; HUMAN; LIVER DYSFUNCTION; MASTALGIA; NAUSEA; NONHUMAN; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR PROMOTION;

BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 77149129286     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3181ce4ae1     Document Type: Review

References (26)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
2. Pichon MF, Broet P, Magdelenat H, et al. Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. Br J Cancer. 1996;73:1545-1551.
3. Parl FF, Schmidt BP, Dupont WD, et al. Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading. Cancer. 1984;54:2237-2242.
4. Bryan RM, Mercer RJ, Bennett RC, et al. Androgen receptors in breast cancer. Cancer. 1984;54:2436-2440.
5. Persijn JP, Korsten CB, Engelsman E. Oestrogen and androgen receptors in breast cancer and response to endocrine therapy. Br Med J. 1975;4:503.
6. Cauley JA, Lucas F, Kuller LH, et al. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 1999;130:270-277.
7. Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1998;90:1292-1299.
8. Veronesi U, Pizzocaro G. Breast cancer in women subsequent to cystic disease of the breast. Surg Gynecol Obstet. 1968;126:529-532.
9. Agoff SN, Swanson PE, Linden H, et al. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol. 2003;120:725-731.
10. Wong, YC, Xie B. The role of androgens in mammary carcinogenesis. Ital J Anat Embryol. 2001;106:111-125.
11. Hackenberg R, Schulz KD. Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen-like steroids. J Steroid Biochem Mol Biol. 1996;56:113-117.
12. Birrell SN, Hall RE, Tilley WD. Role of the androgen receptor in human breast cancer. J Mammary Gland Biol Neoplasia. 1998;3:95-103.
13. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res. 2009;15:2472-2478.
14. Peters AA, Buchanan G, Ricciardelli C, et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res. 2009;69:6131-6140.
15. Doane AS, Danso M, Lal P, et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene. 2006;25:3994-4008.
16. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.
17. Gruvberger S, Ringnér M, Chen Y, et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res. 2001;61:5979-5984.
18. West M, Blancette C, Dressman H, et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA. 2001;98:11462-11467.
19. van 't Veer LJ, Dai H, van de Vijver, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530-536.
20. Pusztai L, Ayers M, Stec J, et al. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogennegative and estrogen-positive tumors. Clin Cancer Res. 2003;9:2406-2415.
21. Kolvenbag GJ, Blackledge GR, Gotting-Smith K. Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development. Prostate. 1998;34:61-72.
22. Tyrrell CJ, Kaisary AV, Iversen P, et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol. 1998;33:447-456.
23. Tyrrell CJ, Payne H, See WA, et al. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiother Oncol. 2005;76:4-10.
24. Bahceci M, Tuzcu A, Canoruc N, et al. Serum C-reactive protein (CRP) levels and insulin resistance in non-obese women with polycystic ovarian syndrome, and effect of bicalutamide on hirsutism, CRP levels and insulin resistance. Horm Res. 2004;62:283-287.
25. Muderris II, Bayram F, Ozcelik B, et al. New alternative treatment in hirsutism: bicalutamide 25 mg/day. Gynecol Endocrinol. 2002;16:63-66.
26. Traina TA, Wolff A, Giri D, et al. Androgen receptor inhibition can stabilize disease in patients with AR(+), ER(-)/PR(-) metastatic breast cancer. Presented at IMPAKT Annual Meeting, May 7-9 2009, Brussels, Belgium.